Jones Financial Companies
BCRX icon

Jones Financial Companies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jones Financial Companies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Buy
16,882
+14,682
+667% +$114K ﹤0.01% 2483
2025
Q4 		$17.2K Buy
2,200
+717
+48% +$5.18K ﹤0.01% 3003
2025
Q3 		$11.3K Buy
1,483
+283
+24% +$2.36K ﹤0.01% 3034
2025
Q2 		$11.2K Sell
1,200
-50
-4% -$466 ﹤0.01% 2826
2025
Q1 		$9.82K Buy
1,250
+1,050
+525% +$8.47K ﹤0.01% 2712
2024
Q4 		$1.5K Buy
+200
New +$1.52K ﹤0.01% 3068
2022
Q2 		– Sell
-400
Closed -$7K – 727
2022
Q1 		$7K Buy
+400
New +$6.42K ﹤0.01% 540

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jones Financial Companies's BCRX Position: Q1 2026 in Review

Jones Financial Companies increased its BioCryst Pharmaceuticals (BCRX) stake by 667% in Q1 2026, buying an estimated $114K and bringing the position to 16,882 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2483.

Jones Financial Companies first reported a position in BCRX in Q1 2022 and has held it in 7 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jones Financial Companies held 16,882 shares of BioCryst Pharmaceuticals worth $158K as of Q1 2026.
  • Jones Financial Companies bought 14,682 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $114K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #2483 holding.
  • Jones Financial Companies first reported a position in BioCryst Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.